Welcome to IsraPharm - Contact us at +972 7337 468 45 (Office)

Contact Us

Office Address

Weizman 14 st., Tel Aviv, Israel

Phone Number

+972 7337 46845 (Office)

Email Address

[email protected]



Add to Wishlist
Add to Wishlist


Indications for the drug Cadcyla

– treatment of patients with metastatic HER2-positive breast cancer previously treated with trastuzumab and a taxane (sequentially or in combination), who received prior treatment for metastatic disease, or who experienced disease progression during or within 6 months after completion of adjuvant therapy;

– adjuvant therapy for patients with early HER2-positive breast cancer and invasive residual tumor after neoadjuvant therapy with a taxane and trastuzumab.

Active ingredient: trasuzumab emtansine

Prescription medicine

Additional information


100 Mg, 160 Mg